Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
260estimated
Sites
37
Countries
Australia, Belgium, Canada +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-19 | actual | When the study began enrolling |
| Primary completion | 2023-07-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Chronic Myelomonocytic Leukemia (CMML)
- Myeloproliferative Neoplasms (MPNs)
Interventions
- Drug: LY3410738
- Drug: Venetoclax
- Drug: Azacitidine
Primary outcomes
what the primary-completion date above is the date OFTo determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
measured Up to 30 months
To assess the activity of LY3410738 as measured by the overall response rate (ORR) per the Investigator assessment
measured Up to 30 months
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed